Moderator: gloria

By admin
An update has been posted for the clinical study “rTMS Therapy for Primary Orthostatic Tremor”. The update mentions that the study is currently recruiting participants. For more information about rTMS and the purpose of the study please see the link below:

If you are interested learning more about what is a Clinical Study and/or what is involved with participation in a clinical study visit the link below:

**This clinical study was funded through the NORD Orthostatic Tremor research grant with contributions from the Orthostatic Tremor community and a special grant from Lundbeck Inc.’s “Raise Your Hand to Fight Rare Diseases” campaign.

Read more about the Orthostatic Tremor research fund at the University of Nebraska Medical Center and the NORD research fund at the following link:

Your help does make a difference! Together we can stand up to OT.
By admin
The information below was included in the December 2016 update:
Dr. Aparna Wagle Shukla, MD, Assistant Professor, Co-Director of Clinical Trials and Director of the TMS (Transcranial Magnetic Stimulation) Physiology Laboratory, Center for Movement Disorders and Neurorestoration at the University of Florida, Gainesville, is just getting set up to begin her clinical trials regarding rTMS (Repetitive Transcranial Magnetic Stimulation) Therapy for Primary Orthostatic Tremor: A Novel Treatment Approach.

Dr. Shukla will be recruiting about 12 patients over the next six to eight weeks and expects to have results by spring of 2017. She will be submitting abstracts for the American Academy of Neurology and Movement Disorders Society meetings to be held in 2017.
By admin
Results: 10 POT subjects (6 females and 4 males, mean age 70.2 ± 8.0 years, mean disease duration 13.5 ± 5.8 years) participated and tolerated the therapy well. Compared to baseline, subjects randomized to the real arm improved significantly on the FABRS standing score (baseline score 1.3; T1 score 2.3; p = 0.02) at T1 than those in the sham arm. With regards to video-rated standing duration time, there was mean increase of 126.0 ± 172.8 sec in the real arm compared to 12.9 ± 49.9 sec in the sham arm that approached significance (p = 0.11). However, at an individual level, there were 8/10 subjects in the real arm showed improvement (figure). No significant improvements were seen at T2.

Conclusions: Low frequency rTMS to cerebellum is a promising therapy for POT however requires confirmation in a larger follow-up study. A longer duration of rTMS will likely result in longer benefits. ... ic-tremor/

Strange discovery today.

I understand that “one leg” issue. I s[…]